Virtu Financial LLC Nektar Therapeutics Transaction History

Virtu Financial LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.9 - $1.83 $52,483 - $106,716	58,315 Added 348.19%	75,063 $93,000
Q1 2024 May 20, 2024	BUY	$0.49 - $0.96 $8,206 - $16,078	16,748 New	16,748 $16,000
Q2 2023 Jul 27, 2023	BUY	$0.53 - $1.03 $7,247 - $14,085	13,675 New	13,675 $8,000
Q4 2022 Feb 15, 2023	BUY	$2.03 - $4.28 $33,279 - $70,166	16,394 New	16,394 $37,000
Q2 2020 Aug 07, 2020	SELL	$16.86 - $23.44 $392,163 - $545,214	-23,260 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$15.87 - $23.12 $369,136 - $537,771	23,260 New	23,260 $502,000
Q3 2019 Nov 20, 2019	SELL	$16.91 - $36.27 $199,199 - $427,260	-11,780 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$31.0 - $36.3 $365,180 - $427,613	11,780 New	11,780 $419,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.